Equities research analysts expect Evofem Biosciences, Inc. (NASDAQ:EVFM) to post earnings of ($0.36) per share for the current quarter, according to Zacks. Three analysts have made estimates for Evofem Biosciences’ earnings, with estimates ranging from ($0.50) to ($0.16). Evofem Biosciences posted earnings of ($0.27) per share in the same quarter last year, which would indicate a negative year over year growth rate of 33.3%. The business is expected to report its next earnings report after the market closes on Thursday, March 4th.
According to Zacks, analysts expect that Evofem Biosciences will report full year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.17) to ($1.98). For the next year, analysts expect that the firm will report earnings of ($1.36) per share, with EPS estimates ranging from ($1.59) to ($1.26). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Evofem Biosciences.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of Evofem Biosciences by 48.6% during the 2nd quarter. Bank of America Corp DE now owns 12,065 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,948 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Evofem Biosciences by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 211,305 shares of the biotechnology company’s stock valued at $509,000 after acquiring an additional 6,120 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Evofem Biosciences by 15.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 51,158 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 7,030 shares in the last quarter. Rhumbline Advisers grew its holdings in Evofem Biosciences by 11.8% during the 4th quarter. Rhumbline Advisers now owns 76,078 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 8,014 shares in the last quarter. Finally, Citigroup Inc. increased its position in shares of Evofem Biosciences by 218.8% in the 4th quarter. Citigroup Inc. now owns 14,609 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 10,026 shares during the last quarter. 44.84% of the stock is currently owned by institutional investors and hedge funds.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
Featured Article: Diluted Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.